drugset / Trial / NCT02024659

Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps

NCT02024659

Phase 2/3 Completed 57 enrolled Beijing Tongren Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

This randomized, double-blind, placebo-controlled clinical trial enrolled subjects with eosinophilic CRSwNP. Subjects were randomized to receive either budesonide inhalation suspension or placebo for 14 days. Visual analogue scales (VAS)of nasal symptoms, endoscopic polyp scores and morning serum cortical levels were assessed pre- and post-treatment. Polyp samples were evaluated for inflammatory cytokines, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by immunoassay; collagen by histochemistry; and frequencies of different inflammatory T cell infiltration by flow cytometry. this study is undertaken to evaluate the efficacy of short-term prescription of budesonide inhalation suspension via transnasal nebulization by clinical and immunologic assessments. As outcome parameters for remodeling, differences in the expression of collagen and albumin were investigated before and after budesonide treatment. Meanwhile, TGF-β, MMPs and TIMPs expression differences in nasal polyps were investigated to explore underlying mechanisms of tissue reconstitution.

Timeline

Start
2010-09
Primary completion
2011-12
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 1 mg Intranasal

Indications